TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns positive
Q1 FY2026 EBITDA was $3.11M, compared with -$8.99M a year earlier. Trailing-twelve-month EBITDA was -$20.95M.
Context
- EBITDA amounted to 73.2% of revenue in FY2025, down 36.8 pp from a year earlier.
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 3 analysts of -$12.66M (+61.7%) for the fiscal year ending Dec 2026, a step up from the -2.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $3.11M+138.1% QoQ
- Last fiscal yearDec 2025
- -$33.05M-2.1% YoY
- LTMMar 2026
- -$20.95M+5.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +134.6% | -8.9% | -143.6 pp |
| 1 year | -2.1% | +61.7% | +63.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (33.05M) USD
- Year-over-year change
- -2.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (33.05M) | -2.1% |
| FY2024 | 2024-12-31 | (32.39M) | +44.8% |
| FY2023 | 2023-12-31 | (58.65M) | -25.4% |
| FY2022 | 2022-12-31 | (46.76M) | -75.7% |
| FY2021 | 2021-12-31 | (26.62M) | — |
EBITDA vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's LTM Mar 2026 EBITDA of -$20.95M is the 2nd highest of the 11 companies compared; the peer median is -$46.13M.
- Its year-over-year change of +5.5% is the 6th highest of 11, against a peer median of -2.7%.
- EBITDA amounts to 46.7% of revenue for TLSI, versus a peer median of 153.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.96M | +165.0% | — | 58.8% | |
| LTM Mar 2026 | -$20.95M | +5.5% | — | 46.7% | |
| LTM Mar 2026 | -$25.7M | +34.0% | — | 17.0% | |
| LTM Mar 2026 | -$34.64M | +5.7% | — | 107.3% | |
| LTM Mar 2026 | -$37.85M | +9.1% | — | 200.6% | |
| LTM Mar 2026 | -$43.26M | -365.8% | — | 40.4% | |
| LTM Dec 2025 | -$49M | -11.0% | — | 376.3% | |
| LTM Mar 2026 | -$51.68M | +9.1% | — | 45.4% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | -$92.94M | -14.3% | — | 5021.0% |
| LTM Mar 2026 | -$110.64M | -31.7% | — | 17902.8% | |
| LTM Mar 2026 | -$262.46M | -2046.7% | — | 8872.8% | |
| Peer median (excluding TLSI) | -$46.13M | -2.7% | — | 153.9% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.4M | 12.4M | 18.51M | 29.43M | 45.15M |
| Cost of Revenue | 1.19M | 2.26M | 2.61M | 4.1M | 6.97M |
| Gross Profit | 7.21M | 10.14M | 15.91M | 25.33M | 38.19M |
| Gross Margin | 85.8% | 81.8% | 85.9% | 86.1% | 84.6% |
| Research & Development | 14.22M | 21.36M | 29.84M | 17.69M | 14.97M |
| Selling, General & Admin | 17.02M | 25.22M | 40.55M | 43.81M | 50.17M |
| Operating Expenses | 31.24M | 46.58M | 70.38M | 61.49M | 65.13M |
| Depreciation & Amortization | 464K | 414K | 684K | 744K | 626K |
| EBITDA | (26.62M) | (46.76M) | (58.65M) | (32.39M) | (33.05M) |
| EBITDA Margin | -316.8% | -377.2% | -316.9% | -110.0% | -73.2% |
| Operating Income | (24.03M) | (36.44M) | (54.48M) | (36.17M) | (26.95M) |
| Operating Margin | -286.1% | -293.9% | -294.3% | -122.9% | -59.7% |
| Interest Income | 0 | 180K | 431K | 404K | 555K |
| Interest Expense | 1.76M | 1K | 16K | 3.09M | 5.54M |
| Other Income / Expenses | (4.81M) | (10.74M) | (4.88M) | 6.13M | (12.27M) |
| Income Before Tax | (28.84M) | (47.18M) | (59.35M) | (30.04M) | (39.22M) |
| Pre-Tax Margin | -343.3% | -380.5% | -320.6% | -102.1% | -86.9% |
| Income Tax Expense | 3K | 9K | 9K | 6K | 7K |
| Net Income | (28.85M) | (47.19M) | (59.36M) | (33.23M) | (39.23M) |
| Net Margin | -343.4% | -380.6% | -320.7% | -112.9% | -86.9% |
| EPS (Basic) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| EPS (Diluted) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| Weighted Avg Shares | 31.25M | 29.61M | 26.47M | 26.5M | 49.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 29.61M | 26.47M | 26.5M | 37.9M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.